Tas F, Aydiner A, Topuz E, Yasasever V, Karadeniz A, Saip P
Dept. of Medical Oncology, Institute of Oncology, University of Istanbul, Turkey.
J Exp Clin Cancer Res. 2000 Dec;19(4):477-81.
The aim of this study is to assess the clinical usefulness of serum assays of carcinoembryonic antigen (CEA), squamous cell carcinoma antigen (SCC), and CYFRA 21.1 in the diagnosis of squamous cell lung cancer. Sixty patients with squamous cell, and twenty-four patients with nonsquamous cell histology of nonsmall cell lung cancer were enrolled in this study. Serum CEA, SCC, and CYFRA 21.1 levels were obtained by commercially available kits. Upper cutoff levels were 10 ng/ml, 3.5 ng/ml, and 3.5 ng/ml, respectively. In squamous cell lung cancer, percentages and 95% confidence interval (CI) of the patients with elevated levels were as follows: for CEA 23.3% (13-36), for SCC 20.0% (10-32), and for CYFRA 21.1 85.0% (73-93). The positivity rate of CYFRA 21.1 was more significant than CEA and SCC in both squamous and nonsquamous cell lung cancer. None of the markers were significant in differentiating squamous/nonsquamous histology. Only tumor marker CEA was significantly elevated in metastatic squamous cell lung cancer (p=0.004). A novel tumor marker CYFRA 21.1 can be used as a reliable tumor marker in diagnosing squamous cell lung cancer. In addition, CEA has an important role in determining metastatic disease.
本研究旨在评估癌胚抗原（CEA）、鳞状细胞癌抗原（SCC）和细胞角蛋白19片段（CYFRA 21.1）血清检测在鳞状细胞肺癌诊断中的临床应用价值。本研究纳入了60例鳞状细胞组织学类型的非小细胞肺癌患者和24例非鳞状细胞组织学类型的非小细胞肺癌患者。采用市售试剂盒检测血清CEA、SCC和CYFRA 21.1水平。其上限水平分别为10 ng/ml、3.5 ng/ml和3.5 ng/ml。在鳞状细胞肺癌中，水平升高患者的百分比及95%置信区间（CI）如下：CEA为23.3%（13 - 36），SCC为20.0%（10 - 32），CYFRA 21.1为85.0%（73 - 93）。在鳞状和非鳞状细胞肺癌中，CYFRA 21.1的阳性率均比CEA和SCC更显著。这些标志物在区分鳞状/非鳞状组织学类型方面均无显著意义。仅肿瘤标志物CEA在转移性鳞状细胞肺癌中显著升高（p = 0.004）。新型肿瘤标志物CYFRA 21.1可作为诊断鳞状细胞肺癌的可靠肿瘤标志物。此外，CEA在判断转移性疾病中具有重要作用。
